Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics (ATOS)
NASDAQ:ATOS
ATOS Stock Chart & Stats
$4.92
>-$0.01(-0.49%)
At close: 4:00 PM EST
$4.92
>-$0.01(-0.49%)
Day’s Range― - ―
52-Week Range$3.76 - $19.33
Previous CloseN/A
Volume314.80K
Average Volume (3M)1.16M
Market Cap
$40.65M
Enterprise Value-$9.48M
Total Cash (Recent Filing)$51.84M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Apr 01, 2026EPS Estimate
-1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding8,611,428
10 Day Avg. Volume1,949,046
30 Day Avg. Volume1,157,820
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.66
Price to Sales (P/S)0.00
P/FCF Ratio-5.64
Enterprise Value/Market Cap-0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit592.31
Enterprise Value/Ebitda0.29
Forecast
1Y Price Target
$68.75Price Target Upside1297.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-4.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyPhase 2 Z-endoxifen data showing a clear progression-free survival benefit and a favorable safety profile versus tamoxifen support the therapy's potential in metastatic breast cancer and de-risk the program clinically.
Duchenne Muscular Dystrophy ExpansionEndoxifen's oral, mutation-agnostic mechanism that upregulates utrophin offers the potential for a broadly applicable, well-tolerated treatment in Duchenne muscular dystrophy, which could drive significant investor interest if clinical signals emerge.
Regulatory IncentivesRare Pediatric Disease designation combined with reauthorization of Priority Review Vouchers could materially increase the commercial value of an approval and attract strategic interest.
Bears Say
Financing And Dilution RiskMarked share price decline has increased market expectations for an equity financing, creating a dilution risk that could pressure returns for current shareholders.
Program Funding RiskAnticipated need to raise capital heightens the risk that clinical programs could be delayed or scaled back if acceptable financing is not secured, potentially slowing development progress.
Share Volatility And Investor ConfidencePersistent share weakness elevates stock volatility and can reduce investor confidence, making the stock more sensitive to negative headlines or failed milestones.
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $3.76 and its highest was $19.33 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $40.65M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 27 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Nov 12, 2025. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.975 by -$0.075.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -1.14.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 8,611,428 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.975. Following the earnings report the stock price went down -1.74%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atossa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.75 (1297.36% Upside)
$68.75 (1297.36% Upside)
Hedge Fund Trend
Increased
By 3.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.34%
12-Months-Change
Fundamentals
Return on Equity
-48.89%
Trailing 12-Months
Asset Growth
-24.86%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
ATOS Stock 12 Month Forecast
Average Price Target
$68.75
▲(1297.36% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---